{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:55:47Z","timestamp":1777881347951,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmol Eye Dis"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      The PRESERFLO\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Microshunt procedure offers a safe and effective alternative to trabeculectomy procedure. The adjuvant use of anti-vascular endothelial growth factor (VEGF) with trabeculectomy has been well studied, yet little is known on the effect and safety of anti-VEGF agents used as an adjunctive therapy in PRESERFLO\n                      <jats:sup>\u00ae<\/jats:sup>\n                      procedures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To compare the outcomes of PRESERFLO Microshunt procedure using either mitomycin C (MMC) alone versus MMC augmented with bevacizumab in patients with open angle glaucoma to a follow-up time of 6\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective observational single-center single-surgeon study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients\u2019 records of patients who consecutively underwent PRESERFLO Microshunt at Queen Victoria Hospital, United Kingdom, were examined. From December 2018 to January 2020, eligible patients underwent PRESERFLO Microshunt implantation with MMC alone (0.2\u20130.4\u2009mg\/ml), whereas from February 2020 to January 2022, patients underwent PRESERFLO Microshunt implantation with MMC (0.2\u20130.4\u2009mg\/ml) and adjuvant intracameral 0.1\u2009ml of bevacizumab (1.25\u2009mg\/0.05\u2009ml). Efficacy outcomes were analyzed, including changes in intraocular pressure (IOP) and changes in medication use. Postoperative complications and postoperative interventions were also reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 75 eyes were included in the analysis, 38 eyes received MMC alone, whereas 37 eyes received MMC combined with bevacizumab. There were no statistically significant differences in the demographic or clinical profile of patients between treatment groups.<\/jats:p>\n                    <jats:p>\n                      Both strategies were effective in terms of IOP lowering (baseline vs 6\u2009months postoperatively: 20.0 (6.8)\u2009mmHg vs 12.8 (3.7)\u2009mmHg in the MMC group; 23.6 (6.9)\u2009mmHg vs 11.9 (4.2)\u2009mmHg in the MMC+ bevacizumab group;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001 in both comparisons). Mean anti-glaucoma medication use also reduced significantly from baseline with no difference between both groups. A higher proportion of patients required postoperative interventions (5-FU injection, needling, and bleb revision) in the MMC alone group (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u200916; 42.1%) compared to the MMC+ bevacizumab group (\n                      <jats:italic toggle=\"yes\">N<\/jats:italic>\n                      \u2009=\u20094; 9.9%) which was statistically significant (Pearson\u2019s \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      test;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Adjuvant use of bevacizumab in MMC-augmented PRESERFLO Microshunt procedure is at least as effective as MMC alone but helps reduce rates of postoperative interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/25158414241287421","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T01:42:28Z","timestamp":1745286148000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of PRESERFLO\n                    <sup>\u00ae<\/sup>\n                    Microshunt procedure with mitomycin C alone versus with mitomycin C and bevacizumab"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9442-0177","authenticated-orcid":false,"given":"Inas","family":"Gadelkarim","sequence":"first","affiliation":[{"name":"Queen Victoria Hospital NHS Foundation Trust, Moorfields Eye Hospital NHS Foundation Trust, University College London, London, UK"},{"name":"Ophthalmology Department, Alexandria University, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8030-1211","authenticated-orcid":false,"given":"Lee","family":"Jones","sequence":"additional","affiliation":[{"name":"Queen Victoria Hospital NHS Foundation Trust, Moorfields Eye Hospital NHS Foundation Trust, University College London, London, UK"},{"name":"Ophthalmology Department, Alexandria University, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umair","family":"Qidwai","sequence":"additional","affiliation":[{"name":"Queen Victoria Hospital NHS Foundation Trust, Moorfields Eye Hospital NHS Foundation Trust, University College London, London, UK"},{"name":"Ophthalmology Department, Alexandria University, Alexandria, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokulan","family":"Ratnarajan","sequence":"additional","affiliation":[{"name":"Corneo-Plastic Unit and Eye Bank, Queen Victoria Hospital NHS Foundation Trust, East Grinstead, West Sussex RH19 3DZ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000000720"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.10.024"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-5632-6_7"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000462"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.b.33525"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000000368"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-019-0162-1"},{"issue":"2","key":"e_1_3_4_9_2","article-title":"5-Fluorouracil for glaucoma surgery","volume":"2014","author":"Green E","year":"2014","unstructured":"Green E, Wilkins M, Bunce C, et al. 5-Fluorouracil for glaucoma surgery. Cochrane Database Syst Rev 2014; 2014(2): CD001132.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"e_1_3_4_10_2","article-title":"Intraoperative mitomycin C for glaucoma surgery","volume":"2005","author":"Wilkins M","year":"2005","unstructured":"Wilkins M, Indar A, Wormald R. Intraoperative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev 2005; 2005(4): CD002897.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000458488"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(87)90091-9"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(03)00038-9"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.028"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317299"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256670"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14968"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.02.020"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogla.2021.07.008"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030657"},{"key":"e_1_3_4_21_2","first-page":"789","article-title":"Nintedanib inhibits TGF-\u03b2-induced myofibroblast transdifferentiation in human Tenon\u2019s fibroblasts","volume":"24","author":"Lin X","year":"2018","unstructured":"Lin X, Wen J, Liu R, et al. Nintedanib inhibits TGF-\u03b2-induced myofibroblast transdifferentiation in human Tenon\u2019s fibroblasts. Mol Vis 2018; 24: 789\u2013800.","journal-title":"Mol Vis"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319039"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003223"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119874682"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-320631"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085782"},{"key":"e_1_3_4_27_2","volume-title":"Clinical decision in glaucoma","author":"Hodapp E","year":"1993","unstructured":"Hodapp E, Parrish RK, Anderson DR. Clinical decision in glaucoma. Mosby, 1993."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/08820538.2016.1154163"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.02.020"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-3148"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2662"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0056"},{"key":"e_1_3_4_33_2","first-page":"3339","article-title":"Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells","volume":"17","author":"Rusovici R","year":"2011","unstructured":"Rusovici R, Sakhalkar M, Chalam KV. Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells. Mol Vis 2011; 17: 3339\u20133346.","journal-title":"Mol Vis"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3928\/1542-8877-20060301-12"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2023-323526"}],"container-title":["Therapeutic Advances in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25158414241287421","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25158414241287421","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25158414241287421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:40:33Z","timestamp":1777596033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25158414241287421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":34,"alternative-id":["10.1177\/25158414241287421"],"URL":"https:\/\/doi.org\/10.1177\/25158414241287421","relation":{},"ISSN":["2515-8414","2515-8414"],"issn-type":[{"value":"2515-8414","type":"print"},{"value":"2515-8414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"article-number":"25158414241287421"}}